7 completed, 6 recruiting, 1 active not recruiting, 1 approved for marketing. 3 Phase 3, 2 Not applicable, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Withdrawn 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Bardet-Biedl Syndrome: new trials by email Literature Review of Bardet-Biedl Syndrome trials Research Report on Bardet-Biedl Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bardet Beidle Syndrome in a Syrian Adolescent : a Rare Case Report Bardet Biedl Syndrome (BBS) | Unknown | Al Baath University | 100 | 2024-10-12 | 2024-09-27 | |
| Early Genetic Identification of Obesity Genetic testing via blood collection - Obesity, Childhood, Hyperphagia | Active not recruiting | Rolfs Consulting und Verwaltungs-GmbH (RCV) | 1000 | 2024-01-24 | 2025-09-29 | |
| Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity Setmelanotide - Bardet Biedl Syndrome (BBS), Bardet Biedl Syndrome | Phase 4 | Recruiting | Tom Hühne | 200 | 2023-01-01 | 2026-06-29 |
| The Effect of GLP1 Agonists on Weight Loss in BBS Cohort in the UK Bardet-Biedl Syndrome | Completed | The Queen Elizabeth Hospital | 300 | 2023-01-01 | 2026-05-27 | |
| Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity Setmelanotide - Bardet-Biedl Syndrome, POMC Deficiency Obesity | Phase 3 | Completed | Rhythm Pharmaceuticals, Inc. | 12 | 2022-03-08 | 2024-11-27 |
| Characterizing the Genotype and Phenotype in Adults With Bardet-Biedl Syndrome No intervention - Bardet-Biedl Syndrome | Completed | Oslo University Hospital | 30 | 2022-02-01 | 2025-08-07 | |
| Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway Setmelanotide 2 mg, Setmelanotide 2.5 mg, Setmelanotide 3 mg - Bardet-Biedl Syndrome, POMC Deficiency | Phase 3 | Completed | Rhythm Pharmaceuticals, Inc. | 19 | 2021-12-21 | 2024-11-26 |
| Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) Blood sample, Urine sample - Ciliopathies, Nephronophthisis | Not applicable | Completed | Assistance Publique - Hôpitaux de Paris | 240 | 2021-11-08 | 2026-05-06 |
| COhort for Bardet-Bield Syndrome and Alström Syndrome for Translational Research Monocentric Interventional Study Skin biopsy - Bardet-Biedl Syndrome, Alström Syndrome | Not applicable | Recruiting | University Hospital, Strasbourg, France | 350 | 2020-06-16 | 2021-09-10 |
| Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity Setmelanotide, Placebo - Bardet Biedl Syndrome (BBS), Alström Syndrome (AS) | Phase 3 | Completed | Rhythm Pharmaceuticals, Inc. | 52 | 2018-11-23 | 2023-12-01 |
| GROWing Up With Rare GENEtic Syndromes Retrospective file studies - Prader-Willi Syndrome, PWS-like Syndrome | Recruiting | dr. Laura C. G. de Graaff-Herder | 600 | 2018-10-01 | 2023-09-06 | |
| Treatment of Bardet-Biedl-Syndrome With Metformin for Evaluation of a Possible Visual Improvement Metformin - Bardet-Biedl Syndrome, Visual Impairment | Phase 2 | Withdrawn | University Hospital Tuebingen | 2018-04-01 | 2019-04-18 | |
| Clinical Registry Investigating Bardet-Biedl Syndrome Bardet-Biedl Syndrome | Recruiting | Marshfield Clinic Research Foundation | 1200 | 2014-06-01 | 2022-07-19 | |
| Inherited Retinal Degenerative Disease Registry Eye Diseases Hereditary, Retinal Disease | Recruiting | Foundation Fighting Blindness | 20000 | 2014-06-01 | 2026-05-19 | |
| ARPKD Database Study Hepato/Renal Fibrocystic Disease, Autosomal Recessive Polycystic Kidney Disease | Recruiting | Children's Hospital of Philadelphia | 200 | 2011-06-01 | 2026-06-15 | |
| Genetics and Clinical Characteristics of Bardet-Biedl Syndrome Bardet-Biedl Syndrome | Terminated | National Human Genome Research Institute (NHGRI) | 194 | 2004-02-17 | 2019-12-04 | |
| Bardet-Biedl Syndrome Study: Clinical and Genetic Epidemiology Study in Adults clinical, biological, and radiological - Bardet-Biedl Syndrome, Orphan Diseases | Completed | University Hospital, Strasbourg, France | 40 | 2003-06-01 | 2008-08-08 | |
| An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS) Setmelanotide, administered subcutaneously [SC], once daily. - Bardet-Biedl Syndrome (BBS), Obesity | Approved for marketing | Rhythm Pharmaceuticals, Inc. | 2022-08-10 |
Obesity (7) · Alstrom Syndrome (3) · Hyperphagia (3) · Polydactyly (3) · Proopiomelanocortin Deficiency (3) · Retinal Diseases (3) · Retinitis Pigmentosa (3) · Agenesis of Cerebellar Vermis (2) · Genetic Diseases, Inborn (2) · Nephronophthisis, familial juvenile (2) · Pediatric Obesity (2) · 22q11 Deletion Syndrome (1) · Abetalipoproteinemia (1) · Achromatopsia 3 (1)
Abnormalities, Multiple (18) · Brain Diseases (18) · Central Nervous System Diseases (18) · Congenital Abnormalities (18) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (18) · Eye Diseases (18) · Hypothalamic Diseases (18) · Nervous System Diseases (18) · Ciliopathies (17) · Eye Diseases, Hereditary (17) · Genetic Diseases, Inborn (16) · Pathological Conditions, Signs and Symptoms (15) · Retinitis Pigmentosa (15) · Signs and Symptoms (14) · Nutritional and Metabolic Diseases (11)
setmelanotide (5) · Biological Products (1) · Blood Specimen Collection (1) · Metformin (1)
Rhythm Pharmaceuticals, Inc. (4) · University Hospital, Strasbourg, France (2) · Al Baath University (1) · Assistance Publique - Hôpitaux de Paris (1) · Children's Hospital of Philadelphia (1) · Foundation Fighting Blindness (1) · Marshfield Clinic Research Foundation (1) · National Human Genome Research Institute (NHGRI) (1) · Oslo University Hospital (1) · Rolfs Consulting und Verwaltungs-GmbH (RCV) (1) · The Queen Elizabeth Hospital (1) · Tom Hühne (1) · University Hospital Tuebingen (1) · dr. Laura C. G. de Graaff-Herder (1)
United States (7) · France (4) · United Kingdom (4) · Germany (3) · Canada (2) · Netherlands (2) · Puerto Rico (2) · Spain (2) · Australia (1) · Norway (1)
David Meeker, MD (3) · Alain Verloes, MD (1) · Arndt Rolfs, PhD, MD (1) · Catherine Arnold, MD (1) · Charlotte von der Lippe, MD, PhD (1) · Christian Brandt, MD (1) · Didier Lacombe, MD (1) · Heiko Billing, PD Dr. med. (1) · J-Louis Mandel, MD (1) · Jeremy Tomlinson, Professor (1) · Leslie G Biesecker, M.D. (1) · Linda Shapiro, M.D., Ph.D. (1) · Lisa Guay-Woodford, MD (1) · Metin Cetiner, PD Dr. med. (1)
PMID 34013094, PMID 36356613, PMID 36647077, PMID 36961653, PMID 39549719, PMID 40262952, PMID 40903014, PMID 41703984, PMID 42157030, PMID 42175648, PMID 42821228
2018 (1), P30DK074038 (1)